Free Trial

InterCure (INCR) Competitors

InterCure logo
$1.54 -0.01 (-0.32%)
Closing price 03:57 PM Eastern
Extended Trading
$1.56 +0.03 (+1.63%)
As of 05:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

INCR vs. ALLO, TVRD, ZYBT, CRDF, MREO, KOD, MNPR, TSVT, AARD, and PRQR

Should you be buying InterCure stock or one of its competitors? The main competitors of InterCure include Allogene Therapeutics (ALLO), Tvardi Therapeutics (TVRD), Zhengye Biotechnology (ZYBT), Cardiff Oncology (CRDF), Mereo BioPharma Group (MREO), Kodiak Sciences (KOD), Monopar Therapeutics (MNPR), 2seventy bio (TSVT), Aardvark Therapeutics (AARD), and ProQR Therapeutics (PRQR). These companies are all part of the "pharmaceutical products" industry.

InterCure vs. Its Competitors

InterCure (NASDAQ:INCR) and Allogene Therapeutics (NASDAQ:ALLO) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, media sentiment, earnings, profitability and institutional ownership.

InterCure has higher revenue and earnings than Allogene Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
InterCure$64.55MN/A-$18.32MN/AN/A
Allogene TherapeuticsN/AN/A-$257.59M-$1.23-1.22

InterCure's return on equity of 0.00% beat Allogene Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
InterCureN/A N/A N/A
Allogene Therapeutics N/A -52.98%-41.28%

Allogene Therapeutics has a consensus target price of $8.44, suggesting a potential upside of 462.96%. Given Allogene Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Allogene Therapeutics is more favorable than InterCure.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
InterCure
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Allogene Therapeutics
0 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.90

InterCure has a beta of 1.18, meaning that its stock price is 18% more volatile than the S&P 500. Comparatively, Allogene Therapeutics has a beta of 0.31, meaning that its stock price is 69% less volatile than the S&P 500.

8.3% of InterCure shares are held by institutional investors. Comparatively, 83.6% of Allogene Therapeutics shares are held by institutional investors. 0.2% of InterCure shares are held by insiders. Comparatively, 13.2% of Allogene Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Allogene Therapeutics had 1 more articles in the media than InterCure. MarketBeat recorded 2 mentions for Allogene Therapeutics and 1 mentions for InterCure. InterCure's average media sentiment score of 1.89 beat Allogene Therapeutics' score of 0.96 indicating that InterCure is being referred to more favorably in the media.

Company Overall Sentiment
InterCure Very Positive
Allogene Therapeutics Positive

Summary

InterCure and Allogene Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

Get InterCure News Delivered to You Automatically

Sign up to receive the latest news and ratings for INCR and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

INCR vs. The Competition

MetricInterCureMED PRODUCTS IndustryMedical SectorNASDAQ Exchange
Market Cap$70.18M$10.55B$5.70B$9.51B
Dividend YieldN/A2.00%4.69%4.01%
P/E RatioN/A17.0728.0720.05
Price / SalesN/A29.18448.5799.42
Price / CashN/A23.0336.2258.56
Price / Book0.653.698.665.87
Net Income-$18.32M$234.77M$3.25B$258.55M
7 Day Performance0.99%6.32%4.20%2.23%
1 Month Performance3.72%8.39%10.82%12.76%
1 Year Performance-36.31%-13.51%34.70%19.36%

InterCure Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
INCR
InterCure
0.661 of 5 stars
$1.54
-0.3%
N/A-34.5%$70.18M$64.55M0.00350Positive News
ALLO
Allogene Therapeutics
3.2575 of 5 stars
$1.29
+0.8%
$8.44
+554.6%
-48.1%$282.16M$20K-1.05310
TVRD
Tvardi Therapeutics
N/A$29.83
+9.1%
$64.25
+115.4%
N/A$279.21M$7.14M0.0080High Trading Volume
ZYBT
Zhengye Biotechnology
N/A$5.87
-0.3%
N/AN/A$276.86M$186.36M0.00278Positive News
Gap Up
CRDF
Cardiff Oncology
1.1483 of 5 stars
$4.13
+1.5%
$11.70
+183.3%
+82.4%$274.77M$680K-4.4920
MREO
Mereo BioPharma Group
1.7907 of 5 stars
$1.72
+6.8%
$7.20
+318.6%
-55.9%$273.48M$10M-24.5740High Trading Volume
KOD
Kodiak Sciences
2.5305 of 5 stars
$5.17
+14.1%
$9.00
+74.1%
+173.2%$272.77MN/A-1.4290
MNPR
Monopar Therapeutics
2.2868 of 5 stars
$43.73
+18.6%
$60.00
+37.2%
+1,363.1%$267.63MN/A-12.5710Positive News
TSVT
2seventy bio
0.3457 of 5 stars
$5.00
flat
$5.00
N/A$266.15M$48.37M-2.69440
AARD
Aardvark Therapeutics
N/A$12.11
-0.5%
$33.00
+172.5%
N/A$262.74MN/A0.0018
PRQR
ProQR Therapeutics
2.8831 of 5 stars
$2.48
+6.9%
$8.00
+222.6%
+20.2%$260.92M$20.46M-7.09180

Related Companies and Tools


This page (NASDAQ:INCR) was last updated on 7/25/2025 by MarketBeat.com Staff
From Our Partners